Physician profile
Alvin E Goldansky
NPI 1104846914
$20,549.04
in general payments reported to CMS, 2019-2025
64 companies · $2,625 in 2025
The $2,625 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,987 · 2020: $2,814 · 2021: $3,567 · 2022: $2,899 · 2023: $2,655 · 2024: $3,002 · 2025: $2,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,281.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,305.57 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,084.45 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $1,948.75 | 2019-2025 | |
| Pfizer INC. | $1,471.36 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,307.97 | 2019-2024 | Jardiance |
| Novo Nordisk INC | $1,209.22 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,118.08 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $1,104.01 | 2019-2025 | Mounjaro, Trulicity, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $859.68 | 2019-2024 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $664.69 | 2019-2025 | Zoryve |
| Astellas Pharma US INC | $501.68 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $456.80 | 2019-2024 | Xifaxan, Trulance |
| Abbott Laboratories | $403.64 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Aveir |
| Amarin Pharma, INC. | $369.09 | 2019-2021 | |
| Lucid Diagnostics INC. | $361.80 | 2021-2022 |
Show all 64 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alvin Goldansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.